Analyst Price Targets — RVTY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 10:39 am | Luke Sergott | Barclays | $95.00 | $92.64 | TheFly | Revvity downgraded to Equal Weight from Overweight at Barclays |
| February 3, 2026 3:05 pm | Catherine Ramsey Schulte | Robert W. Baird | $129.00 | $103.89 | TheFly | Revvity price target raised to $129 from $123 at Baird |
| February 3, 2026 1:10 pm | — | Cowen & Co. | $124.00 | $106.97 | TheFly | Revvity price target raised to $124 from $120 at TD Cowen |
| February 3, 2026 12:55 pm | — | Evercore ISI | $118.00 | $107.09 | TheFly | Revvity price target raised to $118 from $112 at Evercore ISI |
| February 3, 2026 10:28 am | — | Barclays | $118.00 | $107.09 | TheFly | Revvity price target raised to $118 from $115 at Barclays |
| February 2, 2026 7:27 pm | — | Jefferies | $105.00 | $107.05 | TheFly | Revvity price target raised to $105 from $100 at Jefferies |
| December 15, 2025 11:29 am | Brandon Couillard | Wells Fargo | $107.00 | $100.46 | TheFly | Revvity price target raised to $107 from $102 at Wells Fargo |
| December 15, 2025 10:56 am | Luke Sergott | Barclays | $115.00 | $100.46 | TheFly | Revvity price target raised to $115 from $105 at Barclays |
| December 9, 2025 9:28 am | Evie Koslosky | Goldman Sachs | $105.00 | $99.79 | TheFly | Revvity initiated with a Neutral at Goldman Sachs |
| October 28, 2025 11:19 am | — | Robert W. Baird | $123.00 | $97.74 | TheFly | Revvity price target raised to $123 from $122 at Baird |
Latest News for RVTY
Sumitomo Mitsui Trust Group Inc. trimmed its position in Revvity Inc. (NYSE: RVTY) by 86.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,730 shares of the company's stock after selling 235,296 shares during the quarter. Sumitomo
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 9:20 a.m. PT - Steve Willoughby, senior vice president, investor relations, ESG, risk Goldman Sachs 47th Annual Global Healthcare Conference Tuesday, June 9, 2026 8:40 a.m. ET - Prahlad Singh, president and chief…
Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost collaboration in biologics development.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access…
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RVTY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.